Insulet | PODD - Sales Revenues


Insulet reported $801.7M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Abbott USD 12.59B 1.43B Jun/2026
Align Technology USD 1.06B 20M Jun/2026
AtriCure USD 153.6M 12.4M Jun/2026
Baxter International USD 2.96B 260M Jun/2026
Becton, Dickinson and Co. USD 5B 300M Jun/2026
Boston Scientific USD 5.44B 240M Jun/2026
Cardinal Health USD 60.9B 4.73B Mar/2026
Cooper Companies USD 1.08B 57.4M Mar/2026
Dexcom USD 1.31B 120M Jun/2026
Edwards Lifesciences USD 1.74B 90M Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Globus Medical USD 759.85M 66.55M Mar/2026
ICU Medical USD 525.77M 14.93M Mar/2026
Inogen USD 74.93M 504K Sep/2024
Insulet USD 801.7M 40M Jun/2026
Integra LifeSciences USD 418.8M 26.9M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Medtronic USD 9.8B 800M Mar/2026
Merit Medical Systems USD 418.8M 36.9M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Solventum Corp USD 2.2B 190M Jun/2026
Stryker USD 6.6B 600M Jun/2026
Tandem Diabetes Care USD 247.22M 43.18M Mar/2026
Teleflex USD 570.3M 22M Jun/2026
West Pharmaceutical Services USD 872.3M 27.4M Jun/2026
Zimmer Biomet Holdings USD 2.18B 90M Jun/2026